Will Teva be the big winner from Mylan's Perrigo bid? - (Globes via NewsPoints Desk)

  • Citi Research analyst Liav Abraham suggested that Teva stands to benefit most from Mylan's offer to acquire Perrigo, Globes reported Sunday.
  • Although Mylan made an offer last week to purchase Perrigo for about $30 billion, some analysts continue to believe that Teva will still make an offer to acquire Mylan.
  • "If Teva is interested in Mylan, a bid must come soon, but there are a number of challenging factors," Abraham stated, adding "Teva will have to make a hostile takeover, because Mylan's management does not wish to sell the company."
  • Abraham also identified uncertainty regarding Mylan's EpiPen products, a poison pill enacted by Mylan and the complexity of such a transaction as additional challenges for Teva.
  • The analyst said that smaller acquisitions will permit Teva to expand its portfolio and diversify its risks.
  • Abraham indicated that an integration of Actavis' generic business is preferable to purchasing Mylan, noting that the unit does not represent a strategic asset for Actavis.

To read more NewsPoints articles, click here.